Drug intelligence / Profile preview

cyproheptadine + methylphenidate

Development stage
Phase 4
Lead developer
Merck
Modality
Small Molecules
Administration
Oral, Transdermal
01

Overview

Cyproheptadine + methylphenidate is a non-branded combination of two small molecule drugs, each with distinct mechanisms and indications. Cyproheptadine is an antihistamine with additional antiserotonergic and anticholinergic properties, primarily used to treat allergic symptoms but also used off-label for appetite stimulation and to counteract stimulant-induced weight loss or insomnia in patients treated for attention deficit hyperactivity disorder (ADHD)[4][5][7]. Methylphenidate is a central nervous system stimulant commonly prescribed for ADHD and narcolepsy. The combination is sometimes used in clinical practice—though not as a fixed-dose product—to manage side effects such as appetite suppression or insomnia caused by stimulants like methylphenidate[7]. There are no known direct pharmacological interactions between the two agents, but their combined use should be monitored due to potential additive side effects such as sedation or CNS effects[1][2].

02

Targets

DAT (Dopamine plasma membrane transport protein)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)NET (Norepinephrine Transporter)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)5-HT2 (5-HT2 receptor family)

Beyond the preview

Go deeper on cyproheptadine + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyproheptadine + methylphenidate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call